127 related articles for article (PubMed ID: 25568994)
21. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
22. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
24. Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.
Lilliecreutz C; Karlsson H; Spetz Holm AC
PLoS One; 2020; 15(7):e0235202. PubMed ID: 32614875
[TBL] [Abstract][Full Text] [Related]
25. Australian women's needs and preferences for information about human papillomavirus in cervical screening.
McCaffery K; Irwig L
J Med Screen; 2005; 12(3):134-41. PubMed ID: 16156944
[TBL] [Abstract][Full Text] [Related]
26. Cervical Cancer Screening Intervals Preferred by U.S. Women.
Cooper CP; Saraiya M
Am J Prev Med; 2018 Sep; 55(3):389-394. PubMed ID: 30033024
[TBL] [Abstract][Full Text] [Related]
27. Primary HPV testing: U.S. women's awareness and acceptance of an emerging screening modality.
Saraiya M; Kwan A; Cooper CP
Prev Med; 2018 Mar; 108():111-114. PubMed ID: 29277414
[TBL] [Abstract][Full Text] [Related]
28. Socio-economic variations in anticipated adverse reactions to testing HPV positive: Implications for the introduction of primary HPV-based cervical screening.
O'Connor M; O'Leary E; Waller J; Gallagher P; Martin CM; O'Leary JJ; Sharp L;
Prev Med; 2018 Oct; 115():90-96. PubMed ID: 30144488
[TBL] [Abstract][Full Text] [Related]
29. Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania.
Cunningham MS; Skrastins E; Fitzpatrick R; Jindal P; Oneko O; Yeates K; Booth CM; Carpenter J; Aronson KJ
BMJ Open; 2015 Mar; 5(3):e005828. PubMed ID: 25757944
[TBL] [Abstract][Full Text] [Related]
30. Determinants of women's likelihood of vaginal self-sampling for human papillomavirus to screen for cervical cancer in Taiwan: a cross-sectional study.
Chen SL; Hsieh PC; Chou CH; Tzeng YL
BMC Womens Health; 2014 Nov; 14():139. PubMed ID: 25420580
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India.
Duttagupta C; Sengupta S; Roy M; Sengupta D; Chakraborty S; Bhattacharya P; Roy S; Ghosh S
Eur J Cancer Prev; 2002 Oct; 11(5):447-56. PubMed ID: 12394242
[TBL] [Abstract][Full Text] [Related]
32. Knowledge, attitudes, and practices toward cervical cancer prevention among women in Kampong Speu Province, Cambodia.
Touch S; Oh JK
BMC Cancer; 2018 Mar; 18(1):294. PubMed ID: 29544466
[TBL] [Abstract][Full Text] [Related]
33. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
34. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
Fokom Domgue J; Cunningham SA; Yu RK; Shete S
Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
[TBL] [Abstract][Full Text] [Related]
36. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
37. Muslim immigrant women's views on cervical cancer screening and HPV self-sampling in Ontario, Canada.
Vahabi M; Lofters A
BMC Public Health; 2016 Aug; 16(1):868. PubMed ID: 27557928
[TBL] [Abstract][Full Text] [Related]
38. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Li Z; Austin RM; Guo M; Zhao C
Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
[TBL] [Abstract][Full Text] [Related]
39. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
40. Screening for cervical cancer: new alternatives and research.
Lörincz AT
Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
